Biotech News
GlaxoSmithKline and Genmab seek European marketing authorisation of Arzerra™ (ofatumumab) in advanced stage blood cancer
GSK & Genmab announced submission of MAA to EMEA for Arzerra, treatment of CLL, it targets a binding site on the CD20 molecule of B-cells.
